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The elongation factor 2 kinase (eEF2K), likewise known as CaMKIII, has been
demonstrated to be involved in antidepressant responses of NMDA receptor
antagonists. Even so, it remains open whether direct inhibition of eEF2K without altering
up-stream or other signaling pathways affects hippocampal synaptic transmission
and neuronal network synchrony. Inhibition of eEF2K by the selective and potent
eEF2K inhibitor A-484954 induced a fast pre-synaptically mediated enhancement of
synaptic transmission and synchronization of neural network activity. The eEF2K-
inhibition mediated potentiation of synaptic transmission of hippocampal CA1 neurons
is most notably independent of protein synthesis and does not rely on protein kinase
C, protein kinase A or mitogen-activated protein kinase (MAPK)/extracellular signal-
regulated protein kinase 1/2. Moreover, the strengthening of synaptic transmission in
the response to the inhibition of eEF2K was strongly attenuated by the inhibition of
p38 MAPK. In addition, we show the involvement of barium-sensitive and more specific
the TWIK-related potassium-1 (TREK-1) channels in the eEF2K-inhibition mediated
potentiation of synaptic transmission. These findings reveal a novel pathway of eEF2K
mediated regulation of hippocampal synaptic transmission. Further research is required
to study whether such compounds could be beneficial for the development of mood
disorder treatments with a fast-acting antidepressant response.
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INTRODUCTION
Neuronal network activity alteration can be encoded by regulation of a large population of
synapses, which is known as an important mechanism for the determination of the resting state
of brain activity and for balancing learning-mediated changes in synaptic transmission. Impaired
resting state of brain activity underlies several diseases, such as, autism-spectrum disorders, bipolar
disorder (Terwindt et al., 1998), schizophrenia (Dickman and Davis, 2009), as well as major
depression disorder (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013).
Major depression disorder is a common but devastating mood disorder affecting many
people. Studies suggest that inhibition of eEF2K plays an important role in the fast-acting
antidepressant response of some of the available treatments (Autry et al., 2011; Zanos et al., 2016).
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It was shown that a NMDA receptor blockade by ketamine
led to an inhibition of eEF2K followed by enhanced protein
synthesis and potentiation of hippocampal synapses that might
mediate the antidepressant response of this compound (Autry
et al., 2011; Duman et al., 2012; Dwyer and Duman, 2013;
Monteggia et al., 2013). In addition, Zanos et al. (2016) stated
that ketamine is metabolized in vivo to a ketamine derivative
that shows antidepressant responses without blockage of NMDA
receptors. The antidepressant effect of this derivative was still
accompanied by a decrease in the phosphorylation of eEF2,
an increase of synaptic transmission and neuronal network
synchrony (Malinow, 2016; Zanos et al., 2016). eEF2K, also
known as CaMKIII, belongs to the atypical alpha-kinase family
(Ryazanov et al., 1997; Middelbeek et al., 2010) and one of its
substrate – the eEF2 – has been linked to the regulation of
protein synthesis (Taha et al., 2013), but also other substrates
of eEF2K has been identified with potentially different outcome
(Newman et al., 2013; Hu et al., 2014). The eEF2K itself underlies
a complex dependency by upstream signaling pathways that
results to a differently regulated eEF2K under various conditions
and neuronal preparations (Kenney et al., 2014). It remains,
however, unknown whether a specific eEF2K inhibition without
modulation of up-stream or other signaling pathways is sufficient
to alter synaptic transmission. To this end, we aimed to study
the effects of direct eEF2K inhibition of hippocampal synaptic
transmission and neuronal network activity in hippocampal slices
and cultures.
Here, we used the selective and potent inhibitor A-484954
(Chen et al., 2011) and found that the inhibition of eEF2K
caused an enhancement of synaptic transmission in the stratum
radiatum of the hippocampal CA1 region that was independent
of de novo protein synthesis and relied on p38 mitogen-activated
protein kinase (MAPK) activity. We provided also evidence
suggesting a presynaptic origin of the effect due to modulation of
the vesicle release probability. As a potential target, we identified
a barium-sensitive potassium channel, TREK-1. In addition,
application of the eEF2K inhibitor increased the synchronization
of neuronal network activity. These findings suggested a novel
role of eEF2K in regulation of synaptic transmission under
participation of p38 MAPK signaling and TREK-1 channels.
RESULTS
Inhibition of eEF2K by A-484954 Elicits a
Fast fEPSP Potentiation
In the search for specific inhibitors of eEF2K, also known as
CaMKIII (Ryazanov et al., 1997; Middelbeek et al., 2010) the
small molecule inhibitor A-484954 was identified from an Abbott
compound library using high throughput screening (Chen et al.,
2011). This compound possesses a half-maximal inhibitory
concentration (IC50) against eEF2K of 0.28 µM.
To validate the inhibitory effect of A-484954 on eEF2K, we
performed a biochemical protein analysis of the eEF2K substrate
by eEF2 phosphorylation. We did not determine the total amount
of eEF2 because the time between drug application and protein
phosphorylation analysis was short and significant de novo
protein synthesis or degradation of eEF2 was unlikely to have
taken place. To this end, 5 µM A-484954 was applied to the
eEF2K substrate for 8, 16, or 32 min, followed by snap freezing
and storage at −80◦C. On the day of analysis, the CA1 region
was isolated and the resulting eEF2 phosphorylation level was
examined (Yuanxiang et al., 2014). The western blots indicated
that A-484954 significantly prevented the phosphorylation of
eEF2 (Figure 1A). After verification of the efficient inhibition
of eEF2K by A-484954, we looked into the effects of eEF2K
inhibition on hippocampal synaptic transmission. We observed
that the inhibition of eEF2K by A-484954 (5 µM) 20 min
after stable baseline recordings resulted in a fast potentiation
of fEPSPs (131 ± 3.8% at 40 min; n = 9) (Figure 1B), which
differed significantly from drug-free experiments from 20 min
onward. The fEPSP values were 105 ± 2.0% at 40 min (n = 9;
Figure 1C).
A-484954 Induced Potentiation Does Not
Require an Evoked Synaptic
Transmission
To determine whether the potentiation mediated by eEF2K
inhibition required evoked synaptic activity, we took a fEPSP
recording without stimulation of the fEPSPs during the
initial 20 min of drug application (Figure 1D). Under these
conditions, we observed a significantly different (p< 0.01) fEPSP
potentiation (125 ± 3.6% at 45 min; n = 4) in comparison with
drug-free experiments (control: 102 ± 2.3% at 45 min; n = 4).
Because the effect of A-484954 on synapses was independent
of evoked synaptic transmission, all synaptic inputs within the
stratum radiatum were probably changed.
Presynaptic Origin of the A-484954
Induced Synaptic Potentiation
To identify the origin of the effect of the drug on synaptic
transmission, we analyzed the paired-pulse (PP) ratio of fEPSPs
and the frequency and amplitude of miniature excitatory
postsynaptic currents (mEPSCs). Using field potential recordings
of synaptic transmission, we detected that the PP ratio of
fEPSPs decreased significantly after drug application for all inter-
stimulus intervals tested in comparison with PP ratios before
drug application (p < 0.05; Figure 2). We concluded that
these data indicated a modulation of the presynaptic release
probability, which we aimed to investigate in detail using whole-
cell voltage clamp analysis of evoked EPSCs and mEPSCs
(Figures 3 and 4).
To verify whether a presynaptic origin of the potentiation
mediated by eEF2K inhibition underlies the potentiation of
synapses, we performed whole-cell voltage clamp recordings
of evoked EPSCs using a paired pulse stimulation protocol
(interstimulus interval: 50 ms) in hippocampal CA1 neurons. The
recordings revealed that the application of A-484954 significantly
reduced the paired pulse ratio of evoked EPSCs (Figure 3). We
also performed whole-cell voltage clamp recordings of mEPSCs
in CA1 pyramidal cells. Tetrodotoxin (1 µM) and bicuculline
(10 µM) were added to prevent action potential-mediated
glutamate release and to block inhibitory postsynaptic currents,
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FIGURE 1 | Inhibition of eEF2K by A-484954 mediates an input nonspecific potentiation of synaptic transmission. (A) The western blots indicate the
decrease in eEF2 phosphorylation in response to the inhibition of eEF2K in comparison with drug-free samples. The bar graph summarizes the normalized
phosphorylation level of eEF2 for drug applications of 8, 16, and 32 min. The application of A-484954 significantly prevented the phosphorylation of the eEF2K
substrate eEF2. (B) Inhibition of eEF2K by 5 µM A-484954 (black circles, n = 9) elicited a potentiation of fEPSPs that reached a maximum within 10 min. (C) fEPSPs
were recorded under drug-free conditions (control, white circles, n = 9). (D) The effect of A-484954 on synaptic transmission did not require evoked stimulation of
the synapses. The insets indicate representative fEPSP traces before (black line) and after (red line) drug application. Scale bar, 0.5 mV/10 ms. (E) The bar graph
summarizes the fEPSP slope values under different conditions and before (10 min) and during (40 min) drug application. The brackets and/or asterisks indicate a
significant difference (∗∗p < 0.01; ∗∗∗p < 0.001) between control and drug groups. Horizontal black lines indicate the time of drug application.
respectively. The recordings revealed that the application of
A-484954 evoked an increase in mEPSC events over time
(Figures 4A,B) with no alteration of their amplitudes (Figure 4C)
in comparison with drug-free conditions. Thus, inter-event
intervals became smaller (Figure 4D), and the maximal inter-
event intervals for before and during drug application shifted
from 16.5 to 6.5 s (Figure 4E) respectively. The significantly
higher probability of mEPSC appearance after drug application
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FIGURE 2 | Analysis of the paired-pulse ratio (PP ratio) of fEPSPs
indicates a presynaptic origin of eEF2K-inhibition mediated
potentiation. The graph summarizes the PP ratio of fEPSP amplitudes for
before (gray diamond, n = 9) and after (black diamond, n = 9) A-484954. PP
ratios after drug application differed significantly for all inter-stimulus intervals
(bracket, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, paired t-test). Insets
show representative fEPSP traces before and after drug application. Scale
bar: 0.5 mV/20 ms.
was also represented by an increase in mEPSC frequency in
comparison with the value before drug application (Figure 4F).
eEF2K-Inhibition Mediated Potentiation
Does Not Rely on Protein Synthesis
eEF2K and one of its substrate – the eEF2 – has been linked to
the regulation of protein synthesis, however, also other substrates
of eEF2K has been identified that might promote protein-
synthesis independent regulation of cellular processes. Thus, we
were interested to determine whether the effect of A-494854 on
synaptic transmission was dependent on protein synthesis. To
this end, we pre-incubated acute hippocampal slices with the
protein synthesis inhibitor anisomycin (20 µM) for 1 h before the
baseline recording. After an additional 20-min baseline recording
in the presence of the inhibitor, A-484954 (5 µM) was applied
to the artificial cerebrospinal fluid causing a fast potentiation of
fEPSP. No significant difference (p= 0.47) was found between the
A-484954-treated group (119± 1.5% at 40 min; n= 4; Figure 5A)
and pretreated group (131 ± 8.8% at 40 min; n = 4; Figure 5A),
indicating that anisomycin did not prevent eEF2K-inhibition
mediated fEPSP potentiation.
To verify the previous data, we pretreated hippocampal
slices with a different protein synthesis inhibitor, cycloheximide
(100 µM), for 1 h. After 20 min of a stable baseline recording,
A-484954 (5 µM) was applied and induced a fast potentiation of
fEPSP. No significant difference (p = 0.18) was found between
the A-484954-treated group (119 ± 1.5% at 40 min; n = 4;
Figure 5B) and pretreated group (117 ± 2.1% at 40 min;
n = 4; Figure 5B), indicating that cycloheximide did not
prevent eEF2K-inhibition mediated fEPSP potentiation. These
experiments provided evidence that eEF2K-inhibition mediated
potentiation does not rely on protein synthesis.
eEF2K-Inhibition Mediated
fEPSP-Potentiation Does Not rely on
Ca2+/Calmodulin-Dependent Protein
Kinase II (CaMKII), Protein Kinase C
(PKC) or Protein Kinase A (PKA)
Presynaptically localized CaMKII, PKC, and PKA have been
reported to be involved in the regulation of vesicle release
probabilities (Abeliovich et al., 1993; Mayford et al., 1996;
Patterson et al., 2001). A simplified schemata of potential
interactions is shown in Figure 6A (modified from Leenders
and Sheng, 2005). To investigate the potential involvement of
these key pathways we perfused acute hippocampal slices with
specific inhibitors for 1 h before A-484954 application. We did
not observe any change in the potentiation of fEPSP mediated by
eEF2K inhibition by specific inhibitors of CaMKII, PKC, or PKA
(Figure 6). Specifically, the CaMKII inhibitor KN-93 (20µM) did
not attenuate A-484954 induced fEPSP potentiation (Figure 6B);
the PKC inhibitor Gö 6983 (Simons et al., 2012; Vasefi et al.,
2013) did not alter the dynamic of the A-484954 mediated effect
on fEPSPs (Figure 6C); and the inhibition of PKA by KT5720
did not result in any modulation of the drug-induced synaptic
potentiation (Figure 6D).
eEF2K-Inhibition Mediated
fEPSP-Potentiation Relies Partially on
Intracellular Calcium Release
Intracellular calcium release from endoplasmic reticulum (ER)
has been reported to play an important role in the regulation of
neural properties, such as excitability of hippocampal pyramidal
cells (Borde et al., 2000; Shah and Haylett, 2000; Shirasaki
et al., 2001), frequency and amplitude of mEPSCs (Sharma
and Vijayaraghavan, 2003), and presynaptic plasticity (Emptage
et al., 2001; Liang et al., 2002; Martin and Buno, 2003).
We therefore investigated whether the potentiation of fEPSP
mediated by eEF2K inhibition requires calcium release from
intracellular calcium stores. Firstly, we tested thapsigargin, a
non-competitive inhibitor of sarco-endoplasmic reticulum Ca2+-
ATPases (SERCA) that causes depletion of intracellular calcium
stores. We observed that 10 µM thapsigargin provoked an
enhancement of basal synaptic transmission that stabilized within
1 h of incubation (data not shown). After a 20-min stable baseline
recording under thapsigargin, application of A-484954 (5 µM)
enhanced the fEPSP slopes (121 ± 4.8% at 40 min; n = 4;
Figure 7A). The increase in fEPSP slopes did not differ from the
potentiation induced by A-484954 alone (126 ± 3.9% at 40 min;
n= 7; Figure 7A), but was significantly larger than that observed
in drug free experiments (Figure 7D).
In a second step, we evaluated the involvement of the
inositol trisphosphate receptor (InsP3R) in the drug-induced
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FIGURE 3 | Inhibition of eEF2K alters the PP ratio of evoked EPSCs. (A) Traces of 19 evoked EPSCs (gray lines) before and after drug application are shown.
The interstimulus interval was 50 ms. The traces of averaged EPSCs are shown in red. Scale bar: 50 pA/20 ms. Right: Analysis of the traces (19 EPSCs) revealed
that the averaged PP ratio value was reduced after 10 min of drug application (black circle) in comparison with the baseline value (gray circle). (B) The left graph
summarizes the distribution of PP ratios before and during drug application of all recordings in four neurons. The black dot represents an outlier. To the right, the
averaged values of four experiments are presented and the significant effect has been indicated with a bracket and ∗∗ (p < 0.01, p = 0.0027).
potentiation. The intracellular calcium release activated by
InsP3R plays important roles in proliferation, development,
learning, and memory (Bosanac et al., 2002). We tested the
InsP3R antagonist aminoethoxydiphenyl borate (2-APB) and
observed that pretreatment and co-application with A-484954
did not affect the potentiation of fEPSPs. The co-application of A-
484954 with an InsP3R blocker induced a fast fEPSP potentiation
of 132± 7.1% at 40 min (n= 6; Figure 7B). This potentiation was
similar to that observed with the A-484954 alone (126 ± 3.9%
at 40 min; n = 7; Figure 7B) and was significantly larger than
baseline values in drug-free experiments (104 ± 1.7% at 40 min;
n = 7; Figure 7D). Therefore, the data suggest that calcium
release from InsP3R dependent calcium stores is not involved in
the eEF2K-inhibition mediated effect on synaptic potentiation.
Ryanodine receptors (RyRs) at the ER are sensitive to caffeine
and ryanodine and are linked to thapsigargin non-sensitive
calcium stores. These channels respond to minor variations in
intracellular calcium concentrations that causes further release of
calcium (Zucchi and Ronca-Testoni, 1997). Blockage of RyRs by
dantrolene (20 µM) prevented A-484954 (5 µM) induced fEPSP
potentiation to some degree. Co-application of dantrolene and
A-484954 resulted in a potentiation of fEPSP of 117 ± 2.2% at
40 min (n = 7; Figure 7C) in comparison with A-484954 alone
(126 ± 3.9% at 40 min, n = 7; Figure 7C). The remaining fEPSP
potentiation was still significantly larger than the fEPSP values
of drug free experiments (Figure 7D). Thus, only the calcium
release mediated by the activation of RyRs played a partial role
in eEF2K-inhibition mediated potentiation.
Inhibition of p38 MAPK Attenuates
eEF2K-Inhibition Mediated
fEPSP-Potentiation
We looked into various other signaling pathways also known
to be involved in the regulation of vesicle release and
conducted experiments using specific inhibitors against PI3K-
Akt and MEK/ERK (English and Cobb, 2002). LY294002 is an
inhibitor of PI3K that has been shown to be effective at a
concentration of 10 µM in acute hippocampal slices (Chang
et al., 2014). In addition, we tested U0126 as an inhibitor of
MEK 1/2 at a concentration of 10 µM that also has been
shown to be effective in hippocampal slices (Kidambi et al.,
2010). Pretreatment of hippocampal slices with a cocktail of
LY294002 and U0126 for 1 h did not alter fEPSP potentiation
induced by A-484954. The resulting fEPSP potentiation was
123 ± 2.0% (n = 4) at 40 min (Figure 8A) that did not
differ (p = 0.24) from the fEPSP values of the A-484954
group (131 ± 4.2%, n = 9), but was still significantly larger
than that in the control group (drug free; 102 ± 2.4%,
n= 9).
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FIGURE 4 | Increase in mEPSC frequency suggests a presynaptic origin of eEF2K-inhibition mediated potentiation. (A) Representative traces of
whole-cell voltage-clamp recordings of mEPSCs before (gray) and during (black) drug application are depicted. Scale bar: 10 pA/2 s. (B) The histogram summarizes
the distribution of mEPSC amplitudes before (gray bars) and during (black bars) drug application over all events of all recordings (n = 7). (C) The mean amplitude
before (gray bar) and during (black bar) drug application do not differ significantly (n = 7; 7.6 ± 0.7 pA versus 7.8 ± 1.0 pA; ns: p = 0.94). (D) The histogram
indicates the distribution of the inter-event intervals for before (gray) and during (black) drug application for all events of all neurons analyzed (n = 7). (E) The
cumulative probability of inter-event intervals of mEPSCs before (gray) and during (black) drug application differs. Vertical dashed lines indicate the maximal values of
the inter-event intervals before (gray) and during (black) drug application. (F) The mean mEPSC frequencies differ significantly (∗p = 0.0148) before and during drug
application (n = 7, 1.2 ± 0.4 Hz versus 2.0 ± 0.6 Hz).
p38 MAPKs are stress-activated protein kinases that are
activated through extracellular stress, cytokines, growth factor,
and osmotic shock (Cuenda and Rousseau, 2007). In addition, the
p38 MAPK pathway plays an important role in synaptic plasticity
and neurodegenerative diseases (Correa and Eales, 2012). The
p38 MAPK family comprises four isoforms: p38α, p38β, p38γ
and p38δ that act on a variety of substrates, e.g., microtubule-
associated protein tau and transcription factors. SB203580 is a
highly specific cell-permeable inhibitor (English and Cobb, 2002)
of p38α and p38β that can inhibit these isoforms at 10 µM in
hippocampal slices (Capron et al., 2006; Hasegawa et al., 2014).
We tested the involvement of p38 MAPK in the eEF2K-inhibition
mediated fEPSP potentiation by adding 10 µM SB203580 to the
Akt/MEK 1/2 inhibitor cocktail (Figure 8B). We noticed that
this cocktail efficiently eliminated the previously robust A-484954
induced fEPSP potentiation. The fEPSPs (105 ± 4.2% at 40 min;
n = 4; Figure 8B) differed significantly (p = 0.0024) for all time
points tested in comparison with A-494854 alone experiments
(131 ± 3.8% at 40 min; n = 9; Figure 8B). These data suggested
that p38 MAPK is required for the eEF2K-inhibition mediated
fEPSP potentiation.
To confirm the role of p38 MAPK, we incubated the acute
hippocampal slices for 1 h in 10 µM SB203580 containing
ACSF (Figure 8C). Consistent with our previous result, 10 µM
SB203580 alone was sufficient to attenuate the A-484954 induced
fEPSP potentiation, with a significant difference (p = 0.0003)
between the pretreated group (107 ± 0.4% at 40 min; n = 6;
Figure 8C, gray circle) and the non-pretreated group (131± 3.8%
at 40 min; n = 9; Figure 8C, black circle). Application of
SB203580 alone did not show a significant (p = 0.07) effect on
the fEPSP baseline (113 ± 5.6% at 45 min; n = 8; Figure 8D,
black circles). To further determine whether the inhibition of
eEF2K results in an increase of p38 MAPK phosphorylation, we
collected slices after 8-, 16-, or 32-min applications A-484954
(5 µM) for whole-protein biochemical analysis. The western
blot data indicated that A-484954 (5 µM) induced a rapid
phosphorylation of p38 MAPK (Figure 8E), suggesting that
p38 MAPK phosphorylation is altered in response to eEF2K
inhibition and that the p38 MAPK takes part in the A-484954
induced enhancement of synaptic transmission.
Barium Sensitive Potassium Channels
Are Involved in eEF2K-Inhibition
Mediated fEPSP Potentiation
p38 MAPK has been reported to regulate hyperpolarization-
activated cyclic nucleotide-gated (HCN) channels in
hippocampal pyramidal neurons (Poolos et al., 2006; Jung
et al., 2010). We tested whether HCN channels were involved
in eEF2K-inhibition mediated fEPSP potentiation. In these
experiments, the blocker (ZD7288 or Zatebradine) was applied
from the start of baseline recording to the end of the experiment
and showing no effect on fEPSP potentiation (data not shown).
We then tested the broad-spectrum potassium channel
blocker cesium chloride (CsCl). After a stable baseline recording
with CsCl (2 mM), we washed in A-484954 (5 µM) and observed
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FIGURE 5 | eEF2K-inhibition mediated-fEPSP potentiation does not rely on protein synthesis. (A) The graph summarizes the mean values of normalized
fEPSP slopes for different time points and experimental conditions (control: white circles, n = 4; 5 µM A-484954: black circles, n = 4; 20 µM anisomycin: gray
circles, n = 4). (B) Cycloheximide (gray circles, 100 µM, n = 4) did not alter the A-481954-mediated (black circles, n = 4) potentiation of fEPSP. The potentiation of
fEPSP remained significantly higher than that observed under control conditions (no A-481954, white circles, n = 4). Horizontal black lines indicate the application
period of A-484954 and gray lines indicates the application time of protein synthesis inhibitors. The brackets enclose time points with non-significant (ns) differences
between conditions. To the right of the graphs, representative fEPSP traces for the time points 1 and 2 are depicted. Scale bar: 0.5 mV/10 ms.
a fast potentiation of fEPSP (117 ± 4.0% at 40 min; n = 4;
Figure 9A) that was significantly smaller (p = 0.031) than the
values observed in the A-484954 group (135 ± 4.2% at 40 min;
n = 4; Figure 9A). Likewise, we tested the effect of 10 mM
TEA (Figure 9B) and 400 µM BaCl2 (Figure 9C) on eEF2K-
inhibition mediated potentiation. These experiments indicated
that TEA only partially (p = 0.046) affected the drug induced
fEPSP potentiation reaching 119 ± 3.5% (TEA, 40 min, n = 4).
However, similar experiments with BaCl2 attenuated the drug
induced fEPSP potentiation fully as indicated by the fEPSP slope
value of 107 ± 2.3% at the 40 min (n = 6, p = 0.0003). Statistical
analysis revealed a significant difference for all blockers tested
in comparison with experiments with the drug alone. However,
the resulting potentiation for TEA and CsCl, but not for BaCl2,
remained significantly different in comparison with the drug-free
experiments (Figures 9D,E). These results suggest that the eEF2K
inhibition mediated fEPSP potentiation requires especially the
contribution of barium sensitive potassium channels that are not
affected by TEA or CsCl (Wulff and Zhorov, 2008).
The Outward Rectifier Potassium
Channel TREK-1 Is Involved in
eEF2K-Inhibition Mediated fEPSP
Potentiation
Insight into barium sensitive potassium channel family (Wulff
and Zhorov, 2008) gave us a candidate – the outward-rectifier
background potassium channel TREK-1 (also named KCNK2),
which is involved in the control of resting membrane potential
(Ma et al., 2011). This channel has been previously linked to
play important roles in neuroprotection against epileptic seizures
and ischemia. To study a potential involvement of TREK-1 in
the effects of A-484954 on hippocampal synaptic transmission,
we investigated whether fluoxetine, which has been proven to
block TREK-1 (Kennard et al., 2005; Eckert et al., 2011; Moha
ou Maati et al., 2011; Sandoz et al., 2011; Xi et al., 2011) in
a voltage-independent manner (Honore et al., 2002; Kennard
et al., 2005) and also interferes with other signaling pathways
(Edgar et al., 1999; Fumagalli et al., 2005; Stepulak et al., 2008),
attenuates the potentiation of synapses. This compound has
been widely prescribed as a fast-acting treatment of depression
disorders, however, with psychotropic side effects (Alboni et al.,
2015; Bastos et al., 2015; Liang et al., 2015). We observed that
pre-incubation and co-application of fluoxetine with A-484954
prevented the potentiation of fEPSP-slopes (Figures 10A,B).
Inhibition of eEF2K Synchronizes Activity
of Neurons in Primary Hippocampal Cell
Cultures
Increased synchrony of neuronal network has been implicated as
one of the mechanisms to counteract depression and it has been
shown that a ketamine metabolite with anti-depressant effects
increased Gamma oscillation in vivo (Zanos et al., 2016). Here
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FIGURE 6 | eEF2K-inhibition mediated fEPSP-potentiation does not rely on CaMKII, PKC or PKA. (A) The schemata outlines the relation of kinases in the
regulation of vesicle release. (B) Inhibition of CaMKII by KN-93 does not attenuate drug-induced potentiation (control: white circles = 6; 5 µM A-484954: black
circles, n = 6; 20 µM KN-93: gray circles, n = 4). (C) The graph represents data of PKC inhibition experiments (gray circles: n = 4) in comparison to drug-free
(control: white circles, n = 6) and A-484954 (black circles: n = 6) experiments. (D) Inhibition of PKA (KT5720: gray circles, n = 4) did not alter the time course of
fEPSPs in comparison with experiments with the application of A-484954 alone (black circles, n = 6). The drug-induced potentiation remained significantly different
from that in control experiments (white circles, n = 6). Black and gray horizontal lines represent the application period of A-484954 and inhibitors, respectively.
Brackets enclose periods with significant differences (ns: p > 0.05) between groups as specified by the circles. fEPSP traces at time points 1 and 2 are depicted.
Scale bars: 0.5 mV/10 ms.
we tested whether the application of this eEF2K inhibitor would
enhance neuronal network synchronization. We transduced
neurons of primary hippocampal cell cultures with the genetically
encoded calcium sensor GCamp6f and analyzed the changes in
spontaneous fluorescence intensity within individual neurons of
the network (Figure 11). As it is indicated in the fluorescence
images at different time points in Figure 11A, only a few neurons
had a synchronized activity pattern under drug-free conditions
(Figure 11A, left). The application of 5 µM A-484954 enhanced
the number of synchronized neurons per frame (Figure 11A,
right). The peaks of the fluorescence intensity traces of these three
cells (circled in Figure 11A, left) appear simultaneously after
drug application (Figure 11B), indicating the highest degree of
synchronized activity pattern.
To quantify the degree of synchronization of the
neuronal pairs within one culture dish, a Pearson’s
correlation matrix was calculated and the individual
coefficients were presented as a color-coded heat map
matrix (Figure 11C). The coefficients are color-coded
from dark red over white to dark blue, which correspond
to −1, 0, and 1, respectively. This matrix illustrates that
the degree of synchronization increased during drug
application.
We conducted analyses of two more cell cultures and analyzed
more than 130 neurons. The calculation of the Pearson’s
correlation coefficients and construction of the Gaussian fit for
the frequency distribution histograms (Figure 11D) revealed
that A-484954 efficiently increased the coefficients and therefore
the synchronicity of neuronal activity patterns in the cultures.
In addition, a comparison of the averaged coefficients, for the
three cultures, confirmed the significant difference between the
results before and during drug application (Figure 11E). Thus, we
conclude that A-484954 not only alters the efficiency of synaptic
transmission, but also increases the level of synchronicity of
neuronal activity pattern.
DISCUSSION
To investigate whether direct inhibition of eEF2K causes a
potentiation of synaptic transmission, we employed a new small
molecule eEF2K inhibitor to hippocampal slices and analyzed
the effects on the synaptic transmission. The compound A-
484954 was detected in an Abbott compound library using high
throughput screening in a cell free enzymatic assay against
eEF2K. The compound has an IC50 of 0.28 µM against eEF2K
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FIGURE 7 | eEF2K-inhibition mediated fEPSP-potentiation relies partially on intracellular calcium release. (A) Application of thapsigargin (10 µM
thapsigargin: gray circles, n = 4) did not alter A-484954-induced fEPSP potentiation over time (drug-free: control, white circles, n = 7; 5 µM A-484954 alone; black
circles, n = 7). (B) Inhibition of InsP3R-mediated intracellular calcium release (100 µM 2-APB: gray circles, n = 6) did not alter the slope of fEPSP potentiation
(A-484954: black circles, n = 7), which remained significantly different from that in drug-free experiments (white circles, n = 7). (C) Inhibition of ryanodine receptors
(20 µM dantrolene: gray circles, n = 7) significantly attenuated (p = 0.037) the potentiation of fEPSP mediated by eEF2K inhibition in comparison with A-484954
alone (black circles, n = 7). However, experiments with dantrolene gave significantly elevated results in comparison with drug-free measurements (control: white
circles, n = 7). Black and gray lines indicate A-484954 and inhibitor application times, respectively. Brackets indicate significance levels (∗p < 0.05; ns: p > 0.05)
between groups (circles). fEPSP traces for the time points 1 and 2 are depicted. Scale bars: 0.5 mV/10 ms. (D) The bar graph summarizes the observations and
significance levels (brackets, ∗∗p < 0.01, ∗∗∗p < 0.001) for the different experimental conditions in comparison with drug-free (control) experiments for fEPSP slope
values at the 40-min time point.
with little activity against a wide panel of kinases [see in
Figure 3A the selective kinase profile of the Chen et al. (2011)
publication]. In one of the initial papers, the authors tested the
effect of A-484954 on eEF2K in comparison to siRNA assays.
They could indicate the similarity of the effects of reduction
in eEF2 phosphorylation but not growth of cancer cell. The
widely used NH125, however, induced eEF2 phosphorylation
by multiple pathways, instead of suppressing it. In our cell-
based assay (acute hippocampal slice), we could show that
the utilized concentration of A-484954 effectively inhibited the
eEF2K activity by analyzing the phosphorylation level of eEF2.
This was not a test for the compound’s specificity, because
trials of a compound’s specificity in a cell-based system is
hindered by multiple crosslinks between different signaling
pathways inducing positive or negative feedback regulation
of other key regulators. Thus, only cell free assays against
a variety of targets would be an appropriate approach to
test a compound’s specificity (Bain et al., 2007; Chen et al.,
2011), thus we refer by the interpretation of our data on
publications (Chen et al., 2011; Usui et al., 2015; Wang et al.,
2015).
Using the eEF2K inhibitor A-484954, we showed that the
inhibition of eEF2K enhances synaptic transmission by up-
regulation of the vesicle release probability. In addition, the
enhancement of synaptic transmission by A-484954 reached its
maximum also without active stimulation of Schaffer-collateral
fibers. This experiment showed that the enhancement of
synaptic transmission by A-484954 did not require postsynaptic
depolarization induced by an evoked glutamate release. Thus,
it is likely that A-484954 is inducing a potentiation of most
excitatory synapses in the stratum radiatum. Induction of
synaptic potentiation by ketamine and MK-801 does also not
rely on evoked synaptic transmission (Nosyreva et al., 2013).
In addition, the potentiated synaptic response was accompanied
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FIGURE 8 | Inhibition of p38 MAPK attenuates eEF2K-inhibition mediated fEPSP-potentiation. (A) The line graph summarizes the resulting fEPSP slopes
over time under three experimental conditions (control: white circles; 5 µM A-484954: black circles; 10 µM U0126 plus 10 µM LY492002: gray circles). U0126 and
LY492002 are inhibitors of MEK 1/2 and PI3K, respectively. (B) Additional application of a p38 MAPK inhibitor (10 µM SB203580) to the MEK 1/2-PI3K inhibitor
cocktail (gray circles) significantly attenuated the A-484954-mediated potentiation of fEPSP (black circles; p < 0.01, p = 0.0024 at 40 min). The resulting fEPSPs
were similar in size in comparison with drug-free experiments. (C) Application of the p38 MAPK inhibitor alone (gray circles) also prevented the A-484954-mediated
potentiation of fEPSP (black circles) significantly (p < 0.01, p = 0.0003 at 40 min). (D) Application of the p38 MAPK inhibitor alone (black circles) did not alter the
fEPSP baseline (p = 0.07 at 45 min) in comparison with drug-free baseline values (gray circles). Brackets with asterisks indicate the significance level (∗∗p < 0.01 or
ns: p > 0.05) between the groups specified by circles. fEPSP traces at the time points 1 (black) and 2 (red) are depicted. Scale bars: 0.5 mV/10 ms. (E) The left
panel illustrates representative Western blots for p-eEF2, p-p38 MAPK (Thr180/Tyr182) and GAPDH in total protein lysates from the CA1 region without (−) and after
5 µM A-484954 treatment for 8, 16, and 32 min (+). The bar graph summarizes normalized western blot data for p-EF2 and p-p38 MAPK. The phosphorylation
levels of p38 MAPK (Thr180/Tyr182, gray bar) and eEF2 (black bar) were significantly different from the control (drug-free) measurements (∗∗p < 0.01; n = 3/group).
by an enhanced release probability of vesicles without affecting
the amplitude of synaptic events. This type of change has
been commonly attributed to an alteration of the pre-synaptic
glutamate release machinery. A modulation of the glutamate
receptor density or conductance should have changed the
EPSC amplitude without affecting the PP ratio of synaptic
transmission. Thus, the presynaptic origin of the eEF2K effect
is different from the ketamine and MK-801 induced synaptic
potentiation by postsynaptic localized mechanisms (Nosyreva
et al., 2013).
Mechanisms of eEF2K-Inhibition
Mediated Potentiation of Synaptic
Transmission
Ketamine and MK-801 have been found to alter the postsynaptic
AMPA receptor compensation under the involvement of mTOR,
eEF2K and BDNF (Autry et al., 2011; Duman et al., 2012; Dwyer
and Duman, 2013; Monteggia et al., 2013; Nosyreva et al., 2013).
We like to note that the differences between our and ketamine
related study is that the compound A-484954 is inhibiting eEF2K
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FIGURE 9 | Barium sensitive potassium channels are required for eEF2K-inhibition mediated fEPSP potentiation. (A) The graph indicates the fEPSP
slopes over time under three experimental conditions (control: white circles, n = 4; 5 µM A-484954: black circles, n = 4; 2 mM CsCl2: gray circles, n = 4).
(B) Blockage of TEA (10 mM, gray circles)-sensitive potassium channels partially but significantly attenuated A-484954-mediated fEPSP potentiation (black circles,
n = 4). The remaining fEPSP potentiation was still significantly different from that of drug-free experiments (white circles, n = 4). (C) Pre-application with 400 µM
BaCl2 significantly prevented A-484954-mediated fEPSP potentiation (p < 0.01). fEPSP slopes were similar in size to those with drug-free experiments (control:
white circles, n = 4). Horizontal black and gray lines indicate A-484954 and, CsCl, TEA, or BaCl2 application times, respectively. Brackets enclose the time points of
significant differences (∗p < 0.05; ∗∗p < 0.01) between groups (circle) per time point. (D) Representative fEPSP traces for the time points 1 and 2 and compounds
are depicted. Scale bars: 0.5 mV/10 ms. (E) The bar graph summarizes the observations and significance levels (brackets; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001) for
different experimental conditions in comparison with drug-free (control: white bar) experiments for fEPSP slope values at the 40-min time point.
without direct activation of upstream signaling pathways through
the interference with glutamate receptors. This resulted in a very
fast synaptic response to the compound, while Ketamine and
MK-801 related experiments require at least 30 min to alter
synaptic transmission.
One other difference of the effect of direct eEF2K inhibition
on synaptic responses in comparison with data from ketamine
and MK-801 related experiments (Nosyreva et al., 2013) is its
protein synthesis independency. We address this discrepancy
to the complexity of interconnected signaling pathways when
compounds have a large number of interaction partners.
Ketamine itself is well known to affect a wide range of
cellular processes by modulation, e.g., of cholinergic (Yamakura
et al., 2000; Lydic and Baghdoyan, 2002), or aminergic system
(dopamine and noradrenaline) (Kubota et al., 1999; Kamiyama
et al., 2011; Wang et al., 2012; Sleigh et al., 2014) and for its
derivative the targets are even unknown (Zanos et al., 2016).
Thus, a distinct modulation of different signaling pathways might
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FIGURE 10 | TREK-1 is involved in eEF2K-inhibition mediated fEPSP potentiation. (A) The graph outlines fEPSP-slopes over time under three experimental
conditions (control: white circles, n = 4; 5 µM A-484954: black circles, n = 6; 100 µM Fluoxetine + 5 µM A-484954: gray circles, n = 6). The pretreatment and
co-application of hippocampal slices with Fluoxetine and A-484954 significantly blocked A-484954 mediated fEPSP potentiation (p < 0.01). The resulting fEPSP
slopes were similar in size as in the non-drug experiments (control: white circles). Horizontal black and gray lines indicate the A-484954 and Fluoxetine application
period respectively. fEPSP traces for fluoxetine co-application experiments are shown. Scale bars: 0.5 mV/10 ms. (B) The bar graph summarizes averaged
fEPSP-slope values for different experiments at the 10- and 40-min time points. Brackets enclose experimental groups with significant difference (∗∗p < 0.01,
p = 0.0024; ∗∗∗p < 0.001, p = 0.0003).
promote protein synthesis dependent modulation of synaptic
transmission. Only proteomic or phospho-proteomic studies
might be able to visualize the complexity of altered pathways,
e.g., for MK-801 (Guest et al., 2015). In addition, many studies of
the eEF2K function relied on the inhibitors NH125 and Rottlerin
that have been shown recently to act also in an unpredicted
fashion indicating the necessity of further studies to clarify the
interaction partners (Davies et al., 2000; Bender et al., 2016).
One of the identified eEF2K substrates (Newman et al., 2013;
Hu et al., 2014) has been shown to potentially modulate synaptic
transmission in a protein synthesis independent manner (Jiao
and Li, 2011). Another substrate is involved in regulation of
the activity of protein phosphatases (Comerford et al., 2006),
which could in turn modulate the phosphorylation levels of other
key enzymes such as p38 MAPK (Kitatani et al., 2006). Many
indicated interactions need still to be confirmed to take place in
the hippocampus, but the few presented examples and our own
data point toward protein synthesis independent modulation of
cellular processes by eEF2K. However, the specific network of
signaling pathway with its final targets requires further studies.
To discover a new branch of the eEF2K signaling pathway
that might have been altered by the compound, we tested a
variety of key enzymes that have been shown to be involved in
activity-dependent synaptic plasticity and more importantly in
the regulation of neurotransmitter release (Capogna et al., 1995;
Hilfiker et al., 1999). For example, the activation of CaMKII
and PKC have been shown to increase vesicle release by the
phosphorylation of synapsin-I (Ohyama et al., 2002; Ninan and
Arancio, 2004) or Munc-18 (Fujita et al., 1996; Dulubova et al.,
1999) respectively. In addition, PKA can also contribute to the
vesicle release by phosphorylating RIM1α (Lonart et al., 2003),
SNAP-25 (Hepp et al., 2002), Snapin (Thakur et al., 2004) and
Syntaphilin (Boczan et al., 2004). However, in our experiments,
no effects of specific inhibitors of these kinases on the degree of
compound-induced fEPSP potentiation were observed.
A brief rise in the intracellular calcium concentration is known
to be a key step for the evoked release of glutamate from
presynapses. The origin of the increase in intracellular calcium
is manifold and can rely on intracellular calcium release from
ER. This mechanism plays an important role in regulating neural
function, including the excitability of hippocampal pyramidal
cells (Borde et al., 2000; Shah and Haylett, 2000; Shirasaki et al.,
2001), and might determine the frequency and amplitude of
mEPSCs (Sharma and Vijayaraghavan, 2003) and the degree of
presynaptic plasticity (Emptage et al., 2001; Liang et al., 2002;
Martin and Buno, 2003). The release of calcium from the ER
can be induced by the activation of calcium transporter SERCA
(Zucchi and Ronca-Testoni, 1997) or the activation of InsP3
receptors by elevated levels of InsP3. However, depletion of the
calcium contents of the ER by thapsigargin or blockage of InsP3
receptors did not prevent the compound-induced potentiation.
Only the inhibition of RyRs by dantrolene showed a tendency to
attenuate the potentiation of synapses. Interestingly, Reese and
Kavalali (2015) reported a critical role of RyRs in amplifying
NMDA receptor-driven Ca2+ signals at rest for the maintenance
of synaptic potentiation.
As discussed above, signaling pathways relevant to classical
plasticity are not involved in the compound-mediated effects on
synaptic transmission. In addition, we showed that the activity
of the PI3K-Akt and MEK/ERK pathways was not required
for this synaptic potentiation. Only an inhibitor against the
p38 MAPK was shown to prevent the potentiation of synaptic
transmission mediated by eEF2K inhibition efficiently. The
p38 MAPK is activated by multiple mechanisms, including
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FIGURE 11 | Inhibition of eEF2K synchronizes neuronal activity pattern in primary hippocampal cell cultures. (A–C) Images, traces, and heat maps in the
figure represent data from one representative experiment before and during drug application. (A) The time points for the representative frames of a fluorescence
image sequence are indicated under the traces in (B) with arrows and letters or numbers. Dashed circles indicate representative neurons (14, 9, and 13). Scale bar,
100 µm. (B) The time courses of changes in fluorescence intensity for three neurons (color-coded throughout the figure) before and during drug application are
presented. Vertical scale bar: 2000 (F-F0/F0) and horizontal bar: 5 s. (C) The degree of synchronized spike activity of neurons to each other are represented by a
Pearson’s correlation based hierarchical clustering matrices. (D) Theoretical Gaussian fits for the frequency distribution histograms of Pearson’s correlation
coefficients were created for all neuronal pairs of three cultures analyzed before and during drug application. (E) The bar graph summarizes the mean values of
correlation coefficient (CC) matrices. The brackets and asterisks indicate the degree of significant difference (∗p < 0.05) of the coefficients before (0.29 ± 0.11) and
after drug application (0.67 ± 0.08).
extracellular stresses, cytokines, growth factors, and osmotic
shocks (Cuenda and Rousseau, 2007). The regulation of p38
MAPK also provokes much interest due to its role in synaptic
plasticity and neurodegenerative disorders (Correa and Eales,
2012). Indeed, we were able to prove that the inhibition of p38α
and p38β by SB203580 (Capron et al., 2006; Kidambi et al., 2010;
Jin et al., 2013; Hasegawa et al., 2014) prevents the synaptic
potentiation caused by the inhibition of eEF2K. In addition,
we showed that the inhibition of eEF2K did not only attenuate
the phosphorylation of eEF2 but also significantly increased the
phosphorylation level of p38 MAPK within a short time, which
was consistent with the results of another study on eEF2K (Usui
et al., 2015). However, how the inhibition of eEF2K can cause an
enhancement of p38 phosphorylation remains unknown. To date,
we have not found any study that addresses a potential interaction
of the compound A-494854 with upstream components of the
p38 MAPK pathway. A reversed interaction of p38 MAPK on
eEF2K has been shown by the p38-dependent phosphorylation of
MK2/3 and subsequent phosphorylation of Ser-377 of the eEF2K
that slightly inhibited its activity (Knebel et al., 2002).
In the search for potential targets that mediated the synaptic
potentiation, we also focused on potassium channels. For
example, p38 MAPK regulates HCN gate channels (h-channels;
Ih) in hippocampal pyramidal neurons (Poolos et al., 2006;
Jung et al., 2010). However, in our experiments, the inhibition
of the h-channel did not prevent the potentiation of synaptic
transmission mediated by eEF2K inhibition, either the cesium-
and TEA-sensitive potassium channels. Only prevention of the
activation of barium-sensitive potassium channels attenuated the
effect of eEF2K inhibition on synaptic transmission. A channel
that belongs to the two-pore potassium channel family with
specific Ba2+ selectivity is the TREK-1 channel (Wulff and
Zhorov, 2008; Ma et al., 2011). Indeed, blockage of the TREK-1
channel by fluoxetine prevented the eEF2K-inhibition mediated
potentiation. TREK-1 channels are expressed both pre- and post-
synaptically (Honore, 2007; Westphalen et al., 2007; Sandoz et al.,
2009; Veale et al., 2014) and contribute to the maintenance
of the neuronal resting potential and membrane excitability by
opposing depolarization. In response to its phosphorylation,
the outflow of potassium ions is reduced and leads to a slight
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depolarization of the membrane potential. This feature may
account for the effect on the synaptic response by eEF2K
inhibition. Since this receptor can be phosphorylated through
phosphorylation by PKC and PKA (Murbartian et al., 2005),
it may also represent a direct target of p38 MAPK which
need further validation. The interpretation of the effects of the
compound fluoxetine on eEF2K mediated synaptic responses is
complicated by its interference with pathways such as PKC, PKA,
or ERK (Edgar et al., 1999; Fumagalli et al., 2005; Stepulak et al.,
2008). Nevertheless, we think that we can rule out some of its
side effects due to our experiments that excluded the involvement
of PKC, PKA, and ERK in the eEF2K-inhibition effect. Further
research is required using genetically modified animals or more
specific antagonist against TREK-1. With regard to the potential
involvement of TREK-1 in neurological diseases, it has been
already shown that TREK-1 can be beneficial against mood
disorders. Genetic deletion of the background potassium channel
TREK-1 creates immunity to depression-inducing paradigms
(Heurteaux et al., 2006; Mazella et al., 2010; Borsotto et al., 2015;
Vivier et al., 2016). Therefore, these results suggest a possibility to
regulate TREK-1 by specific modulation of eEF2K activity.
Synchronization of Neuronal Network
Activity by Overall Regulation of Synaptic
Transmission
We showed that A-484954 induced a synchronization of the
neural network in primary hippocampal cell cultures. A previous
study showed that the regulation of dendrotoxin-sensitive
potassium channels contributes to the pattern of neuronal activity
(Cudmore et al., 2010). Similarly, our data show the potential
implication of barium-sensitive potassium channel TREK-1 in
the regulation of neural network activity.
The synchrony of neuronal network activity is an important
parameter for physiological function of cognitive abilities (Llinas
and Ribary, 2001). Many studies have reported that alteration
in the mechanisms of synchrony of neuronal networks could
alter the cognitive abilities of schizophrenic and autistic and
Alzheimer’s disease patients and can induce motor dysfunctions
(Uhlhaas and Singer, 2006). In addition, high levels of
p-eEF2 were also reported in a mouse model of Alzheimer’s
disease (Li et al., 2005) and in brain material of patients
affected by Alzheimer’s disease, suggesting a particular role of
the eEF2K/eEF2 pathway in mental disorders. Moreover, the
pharmacological and genetic inhibition of eEF2K was recently
reported to be able to reverse the epileptic phenotype in a
mouse model of human epilepsy (Heise et al., 2016). These
data show a novel role of eEF2K in the regulation of brain
network activity, providing a novel target for brain disorder
treatment.
CONCLUSION
We have presented experimental data concerning a novel role
of eEF2K in hippocampal synaptic transmission (Figure 12).
Further research is required to study whether such compounds
could be beneficial for the development of mood disorder
treatments with a fast-acting antidepressant response without
dissociative psychedelic effects.
MATERIALS AND METHODS
Animals
Sprague Dawley rats (aged 6–10 weeks) were provided from
the animal center of the Chinese Academy of Sciences (CAS,
Shanghai, China). The animals were maintained in accordance
with the established standards of animal care and procedures
of the Institutes of Brain Science and State Key Laboratory of
Medical Neurobiology of Fudan University, Shanghai, China.
Efforts were made to minimize the number of animals studied.
Electrophysiology
Hippocampal Slice Preparation
The preparation of acute hippocampal slices closely followed
previously published methodologies (Behnisch et al., 2011; Zhu
et al., 2012; Huang et al., 2015). Briefly, after anaesthetization
with isoflurane, brains were immersed in ice-cold ACSF
(95% O2/5% CO2 and composition in mM: 124 NaCl, 2.5
KCl, 2.5 CaCl2, 2 MgCl2·6 H2O, 1.25 KH2PO4, 10 glucose,
26 NaHCO3, pH 7.3–7.4). Immediately after preparation
of the slices, the CA3 area was disconnected from the CA1
region in all experiments to prevent the propagation of
spontaneous recurrent activity from CA3 pyramidal neurons.
These transverse hippocampal slices (400 µm) were incubated
in a submersion-incubation chamber at 30◦C for at least
1 h. Electrophysiological experiments were performed in
a submerged type recording chamber system (Warner
Instruments, RC-26GLP) mounted on a Nikon Eclipse FN1
microscope with constant perfusion (4 mL/min) of ACSF
at 30◦C.
Field Potential Recording
Field excitatory postsynaptic potentials (fEPSPs) were recorded
in the stratum radiatum of the hippocampal CA1 area via
borosilicate micropipettes filled with ACSF (Huang et al.,
2015). Unipolar stimulation electrodes were applied to stimulate
Schaffer collateral fibers every minute. Recorded field potentials
were amplified by MultiClamp 700B (Axon, USA) and then
digitized at a sample frequency of 20 kHz and filtered
(2.8 kHz low-pass, 0.1 Hz high-pass). Stimulation strengths
were adjusted to 40–50% of the maximum fEPSP slope
values. fEPSP slopes or fEPSP amplitudes were determined
and expressed as a percentage of baseline values (before drug
application).
Whole-Cell Voltage-Clamp Recording
Miniature excitatory postsynaptic currents (mEPSCs) of CA1
neurons were recorded using 5–6 MOhm pipettes filled with
a solution containing (in mM): cesium methanesulfonate 110,
CsCl 10, MgCl2·6H2O 2, EGTA 0.5, ATP-Na2 4, GTP-Na 0.4,
phosphocreatine-Na2 10, creatine phosphokinase 50, pH 7.25.
Tetrodotoxin (1 µM) and bicuculline (10 µM) were added
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FIGURE 12 | Potential elements of the eEF2K-inhibition mediated potentiation. The sketch to the left indicates some of the components studied and their
interaction or activity during baseline stimulation. To the right, the modulation of the phosphorylation level and the resulting synaptic potentiation after
eEF2K-inhibition are presented. The color of the text corresponds to the potentiation indicated above the sketch. Dotted lines: unknown pathways of interaction;
lines ending with a stroke: inhibition; lines ending with a P: phosphorylation. A hypothesis based on our data implicates that the inhibition of eEF2K mediates a
potentiation of synaptic transmission by altering the release probability of vesicles with the participation of p38 MAPK and potassium channel
phosphorylation-mediated reduction of the resting membrane potential at the synaptic button.
to ACSF to prevent action potential-driven transmitter release
and blockage of GABAA receptors. mEPSCs were amplified
by a MultiClamp 700B amplifier, digitalized with Digidata
1440A, and acquired by Clampex 10.2 software (Molecular
Devices, Sunnyvale, CA, USA). Membrane potentials were held at
−72 mV and currents were passed through a 2.8 kHz Bessel filter.
The amplitude and frequency of the mEPSCs were analyzed using
MiniAnalysis 6 (Synaptosoft Inc., Fort Lee, NJ, USA). mEPSCs
were collected at intervals of 3 min before and 20 min after drug
or vehicle application.
Drug Treatment
A-484954 (Sigma–Aldrich, SML0861), TTX (Sigma–Aldrich,
T8024), Bicuculline (Tocris, 2503), Anisomycin (Sigma–Aldrich,
A9789), Cycloheximide (Sigma–Aldrich, C1988), KN-93
(Sigma–Aldrich, K1385), Gö 6983 (Sigma–Aldrich, G1918),
KT5720 (Tocris, 1288), Thapsigargin (Sigma–Aldrich, T9033),
2-APB (Sigma–Aldrich, D9754), Dantrolene (Sigma–Aldrich,
D9175), U0126 (Sigma–Aldrich, U120), LY294002 (Sigma–
Aldrich, L9908), SB203580 (Sigma–Aldrich, S8307), CsCl
(Sigma–Aldrich, C3032), TEA (Sigma–Aldrich, T2265), BaCl2
(Sigma–Aldrich, 342920), and Fluoxetine (Sigma–Aldrich, F132)
were added to ACSF as indicated.
Hippocampal slices were pretreated with these drugs for
1 h, and fEPSPs were recorded in stratum radiatum of
CA1 area. A-484954 was applied after at least 20-min stable
baseline.
Protein Biochemistry
The antibodies and supplier of primary antibodies: rabbit anti-
p-eEF2 (Thr56) (1:1000; Cell Signaling Technology: 2331);
rabbit anti-p-p38 MAPK (Thr180/Tyr182) (1:1000; Cell Signaling
Technology: 4511); rabbit anti-GAPDH (1:1000; Cell Signaling
Technology: 2118); rabbit anti-β-actin (1:1000; Cell Signaling
Technology: 4970).
Secondary antibodies: horseradish peroxidase-conjugated
goat anti-rabbit (1:10000; Jackson ImmunoResearch West Grove:
111-035-003); horseradish peroxidase-conjugated goat anti-
mouse (1:10000; Jackson ImmunoResearch West Grove: 115-
035-003).
Whole cell proteins were extracted from a 400-µm CA1
region of hippocampal slices using RIPA lysis buffer [Beyotime:
Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS and sodium orthovanadate, sodium
fluoride, EDTA, leupeptin] with protease inhibitor (Roche:
04693124001) and phosphatase inhibitor (Roche: 04906837001).
After ultrasonication (15 min), the samples were centrifuged
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(12000 rpm, 5 min) and the supernatant was removed from the
pellet, mixed with 4 × SDS loading buffer, boiled for 10 min and
then stored at −80◦C. Protein concentrations were determined
by the bicinchoninic acid method (BCA Protein Assay Kit,
Beyotime: P0012S, China). Equal amounts of proteins were
separated on an SDS gradient gel and then transferred onto
polyvinylidene difluoride membranes (Millipore: IPVH00010).
After blocking in 5% fat-free milk for 1 h, the membranes
were incubated with primary antibodies overnight at 4◦C. On
the next day, the membranes were washed and incubated with
secondary antibodies. The blots were then incubated with the
chemofluorescent reagent ECL (Thermo Scientific, Rockford, IL,
USA).
Cell Culture
Primary hippocampal neuronal cultures were prepared from
P1 old Sprague Dawley rats following standard protocols. The
cultures were kept for 2 weeks at 37◦C in the 95% O2/5% CO2
incubator. After 2 weeks, the cultures were transduced with a
GCamp6f expressed by the addition of 1 µl non-diluted AAV9
titer.
Calcium Imaging
Cover slides with the primary hippocampal cell cultures at
DIV 12 were transferred to a submerged type recording
chamber system (Warner Instruments, RC-26GLP) 1 week after
transduction of the neurons with GCamp6f. The neurons were
imaged through a 16x water dipping objective (16x, NA: 0.8;
Nikon). Fluorescence proteins were excited by blue light (X-
Cite 120LED; Lumen Dynamics Group, Canada). A sequence of
frames was acquired for 69.5 s at 46 fps using a PCO.edge 5.5
(PCO, Germany) CMOS camera mounted on a Nikon Eclipse
FN1 microscope.
An averaged image over all frames was then subtracted from
the individual frames of a sequence (ImageJ). This procedure
reduced the appearance of neurons that did not alter their
fluorescence over time. Then every remaining neuron was labeled
with a region of interest and the maximum gray values for
every frame and neuron were calculated. In SPSS, each pair of
the neurons were cross-correlated by intensity versus time. The
heat map of resulting Pearson’s correlation coefficients for the
individual pairs were generated using R programming language.
To generate a signal intensity heat map and analog traces, the
values were further normalized in GraphPad by the average gray
values of the initial 2 s of the sequence (F0). The normalized
values were plotted as (F-F0)/F0.
Statistical Analysis
All data are expressed as mean ± standard error of mean
(SEM). The values of different experimental conditions were
compared using two-sided paired or non-paired t-test. A p< 0.05
was considered to indicate a statistically significant difference
between two groups. Drug experiments were interspersed with
drug-free controls.
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